drugset / Trial / NCT05591235
Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
Although, a number of drugs are promising treatment strategies for insulin resistance, a critical question arises to which drug benefits patients with type 2 diabetes more from reduced insulin resistance and consequent glycemic control. In this study, we aim to evaluate the effect of metformin, dapagliflozin and the fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone) on insulin sensitivity and glycemic control in overweight patients with newly diagnosed type 2 diabetes.
Timeline
- Start
- 2022-11
- Primary completion
- 2022-12
- Completion
- 2023-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 100 mg | — |
| Comparator | Metformin | Small molecule | 500 mg | — |
| Comparator | Pioglitazone | Small molecule | 15 mg | — |